TSE:HLS HLS Therapeutics (HLS) Stock Price, News & Analysis C$4.53 -0.06 (-1.31%) As of 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About HLS Therapeutics Stock (TSE:HLS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HLS Therapeutics alerts:Sign Up Key Stats Today's RangeC$4.53▼C$4.6950-Day RangeC$4.27▼C$4.7152-Week RangeC$4.22▼C$5.77Volume16,633 shsAverage Volume8,571 shsMarket CapitalizationC$141.67 millionP/E RatioN/ADividend Yield4.30%Price TargetC$6.00Consensus RatingN/A Company Overview HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world. Read More Receive HLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HLS Stock News HeadlinesHLS Therapeutics Inc (HLTRF) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...May 16 at 1:20 PM | finance.yahoo.comHLS Therapeutics to Host Q1 2026 Financial Results Conference CallMay 1, 2026 | finance.yahoo.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 19 at 1:00 AM | InvestorPlace (Ad)HLS Therapeutics to Present at the 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 14, 2026 | finance.yahoo.comHLS Therapeutics Inc (HLTRF) Q4 2025 Earnings Call Highlights: Strong EBITDA Growth and ...March 12, 2026 | finance.yahoo.comHLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular DiseaseMarch 5, 2026 | finance.yahoo.comHLS Therapeutics to Host Fiscal 2025 Financial Results Conference CallFebruary 26, 2026 | finance.yahoo.comRaymond James Sticks to Its Buy Rating for HLS Therapeutics Inc (HLS)November 21, 2025 | theglobeandmail.comSee More Headlines HLS Stock Analysis - Frequently Asked Questions How have HLS shares performed this year? HLS Therapeutics' stock was trading at C$4.82 at the start of the year. Since then, HLS stock has decreased by 6.0% and is now trading at C$4.53. How were HLS Therapeutics' earnings last quarter? HLS Therapeutics Inc. (TSE:HLS) issued its quarterly earnings data on Friday, May, 15th. The company reported ($0.10) earnings per share for the quarter. The company had revenue of $17.88 million for the quarter. HLS Therapeutics had a negative net margin of 18.42% and a negative trailing twelve-month return on equity of 16.54%. Read the conference call transcript. How do I buy shares of HLS Therapeutics? Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of HLS Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that HLS Therapeutics investors own include Toronto-Dominion Bank (TD), Meta Platforms (META), NVIDIA (NVDA), CohBar (CWBR), Alphabet (GOOG), Great-West Lifeco (GWO) and ObsEva (OBSV). Company Calendar Last Earnings5/15/2026Today5/19/2026AGM 20266/26/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:HLS CIKN/A Webwww.hlstherapeutics.com Phone647-495-9000FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Price Target for HLS TherapeuticsC$6.00 High Price TargetC$6.00 Low Price TargetC$6.00 Potential Upside/Downside+32.5%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Trailing Twelve Months)C($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$15.53 million Net Margins-18.42% Pretax MarginN/A Return on Equity-16.54% Return on Assets-2.89% Debt Debt-to-Equity Ratio75.00 Current Ratio1.00 Quick Ratio1.01 Sales & Book Value Annual SalesC$55.74 million Price / Sales2.54 Cash FlowC$0.30 per share Price / Cash Flow15.22 Book ValueC$1.87 per share Price / Book2.42Miscellaneous Outstanding Shares31,274,000Free FloatN/AMarket CapC$141.67 million OptionableNot Optionable Beta0.39 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (TSE:HLS) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HLS Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HLS Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
